[Innovative practices in the diagnosis and treatment of peritoneal surface malignancies: insights from the 15th congress of the Peritoneal Surface Oncology Group International (PSOGI)].

Based on the highlights of the 15th International Congress on Peritoneal Surface Malignancies (PSOGI), this article discusses innovative practices in the diagnosis and treatment of peritoneal surface malignancies (PSM). The conference focused on optimizing cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). Notably, the CAIRO-6 trial demonstrated that perioperative systemic therapy improves progression-free survival (PFS), while the ORCHESTRA trial provided valuable evidence for the management of synchronous peritoneal and extra-peritoneal metastases. The congress also highlighted the clinical significance of tumor biology and focused on emerging technologies such as Chimeric Antigen Receptor T-cell (CAR-T) therapy and Radspherin. Furthermore, it emphasized the importance of multidisciplinary collaboration and individualized treatment, providing significant insights for the standardization and innovative development of PSM management.